Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 6/20 | 0.68 |
| ▸ | CCNK | O75909 | 1/20 | 0.63 |
| ▸ | CDK13 | Q14004 | 1/20 | 0.63 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.63 |
| ▸ | PAK1 | Q13153 | 5/20 | 0.62 |
| ▸ | PAK4 | O96013 | 4/20 | 0.62 |
| ▸ | NEK1 | Q96PY6 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30558769 | 1.00 | IGF1R (0.68) | IGF1RCCNKCDK13CDK12PAK1 | |
| SCHEMBL25370935 | 0.88 | IGF1R (0.59) | IGF1RCCNKCDK13CDK12PAK1 | |
| SCHEMBL26047955 | 0.87 | CCNK (0.66) | IGF1RCCNKCDK13CDK12PAK1 | |
| SCHEMBL25368424 | 0.84 | IGF1R (0.54) | IGF1RCCNKCDK13CDK12PAK1 | |
| SCHEMBL30558788 | 0.84 | IGF1R (0.54) | IGF1RCCNKCDK13CDK12PAK1 | |
| SCHEMBL26049032 | 0.83 | PAK1 (0.58) | IGF1RCCNKCDK13CDK12PAK1 | |
| SCHEMBL26273491 | 0.80 | NEK1 (0.72) | IGF1RCCNKCDK13CDK12PAK1 | |
| SCHEMBL26050905 | 0.80 | PAK1 (0.53) | IGF1RCCNKCDK13CDK12PAK1 | |
| SCHEMBL26049061 | 0.79 | PAK1 (0.57) | IGF1RCCNKCDK13CDK12PAK1 | |
| SCHEMBL26047950 | 0.78 | IGF1R (0.49) | IGF1RCCNKCDK13CDK12PAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250170130-A1 | MODULATORS OF MYC FAMILY PROTO-ONCOGENE PROTEIN | NALO THERAPEUTICS (US) | 2025-05-29 | — | — | US | disclosed |
| WO-2023163712-A1 | MODULATORS OF MYC FAMILY PROTO-ONCOGENE PROTEIN | NALO THERAPEUTICS (US) | 2023-08-31 | — | — | WO | disclosed |
| WO-2023163712-A1 | MODULATORS OF MYC FAMILY PROTO-ONCOGENE PROTEIN | NALO THERAPEUTICS (US) | 2023-08-31 | — | — | WO | disclosed |
| WO-2023164611-A1 | MODULATORS OF MYC FAMILY PROTO-ONCOGENE PROTEIN | NALO THERAPEUTICS (US) | 2023-08-31 | — | — | WO | disclosed |
| WO-2023164611-A1 | MODULATORS OF MYC FAMILY PROTO-ONCOGENE PROTEIN | NALO THERAPEUTICS (US) | 2023-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250170130-A1 | MODULATORS OF MYC FAMILY PROTO-ONCOGENE PROTEIN | MYC, MYCBP, MYCBP2 | IGF1R 1878/4885CCNK 185/4885CDK13 848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.